Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sorrento Therapeutics Inc (NQ: SRNE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sorrento Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients
Via Benzinga
The Biotech Company That's Training Immune Cells To Fight Cancer
Photo by National Cancer Institute on Unsplash Dr. Henry Ji, President and CEO of Sorrento Therapeutics (NASDAQ: SRNE), was a guest speaker at Benzinga’s All Access on March 25, 2022. 
Via Benzinga
10 Biggest Price Target Changes For Friday
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading. 
Via Benzinga
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight... 
Via FinancialNewsMedia
Exposures COVID-19
Sorrento's Chimeric mRNA COVID-19 Vaccine Candidate Shows Preclinical Action Against Omicron Variants
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Sorrento's COVID-19 Main Protease Inhibitor Neutralizes Omicron
Sorrento Therapeutics Inc's (NASDAQ: SRNE) late-stage preclinical Mpro inhibitor, STI-1558,  
Via Benzinga
The Week In SPAC News: Digital World Under Pressure As Truth Social Rank Slides
In SPAC news this week, Digital World Acquisition was in the spotlight after Truth Social dropped out of the App Store's top 125. Meanwhile, Bridgetown 2 shareholders approved the previously announced... 
Via Talk Markets
Sorrento's Pain Company Reveals Final Results For SP-102 Data For Sciatica Pain Management
Sorrento Therapeutics Inc's (NASDAQ: SRNE) subsidiary Scilex Holding Company has announced final results from its SP-102 Phase 3 Pivotal Trial C.L.E.A.R. Program.  SP-102 (Semdexa) has received Fast... 
Via Benzinga
Vickers Venture SPAC To Merge With Sorrento Therapeutics' Pain-Focused Subsidiary
Vickers Venture Partners' special purpose acquisition company Vickers Vantage Corp I (NASDAQ: VCKA) will merge with Scilex Holding Company, focused on developing and commercializing non-opioid... 
Via Benzinga
Newman Ferrara LLP Announces Corporate Governance Investigation of Sorrento Therapeutics, Inc. – SRNE
From Newman Ferrara LLP
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 42.8% to $0.6 during Monday's regular session. As of 12:30 EST, Calithera Biosciences's stock... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to... 
Via Benzinga
Market Briefing For Wednesday, Jan. 26
The multiple U-turns Tuesday, instead of more consolidation just ahead of the Fed's decision, reflects the character of 'take no prisoners', buy the dips, and run for the hills. 
Via Talk Markets
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant
Sorrento Therapeutics Inc (NASDAQ: SRNE) has released new data on STI-9167, an advanced stage antibody against COVID-19. The antibody was discovered and developed in an... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to... 
Via Benzinga
Market Briefing For Monday, Jan. 10
For the new week perhaps some consolidation and then an effort to improve the market's tone; especially as the small-caps should be entitled to bounce. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today?
NRx is seeking breakthrough designation for its treatment based on new, favorable data on the drug. NRXP stock is climbing on the news. 
Via InvestorPlace
Market Briefing For Wednesday, Dec. 29
Concerns are still with the market and there are broad S&P assumptions about renewed upward behavior. Maybe, but it will be mixed. 
Via Talk Markets
Market Briefing For Tuesday, Dec. 28
'Treacherous' is the term widely-applied to the coming dichotomy of 2022. It encompasses both the questions of 'living with' COVID and 'living with Fed monetary policy. 
Via Talk Markets
PreMarket Prep Stock Of The Day: Sorrento Therapeutics
This deep into the pandemic, positive vaccine or testing-related news doesn't always elicit the same type of reaction as in the early stages of the virus. A good... 
Via Benzinga
Market Briefing For Thursday, Dec. 23
'Fortune favors the brave' it is said; it's partially so in this market, where we certainly got the ignition Tuesday of the seasonal rebound we looked for and more on Wednesday. 
Via Talk Markets
Market Briefing For Wednesday, Dec. 22
Glimmers of hope are not 'yet' overwhelmed by monetary policy snugging, as the market 'for now' has tailwinds that justified buying recent speculations during purges. 
Via Talk Markets
Market Briefing For Tuesday, Dec. 21
Snowstorms don't have to be blizzards. This market has recently been more akin to a 'ground blizzard', where snow is lifted, falling and more or less blowing around. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.